Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Above 200-Day Moving Average – Time to Sell?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $13.46 and traded as high as $13.50. Enanta Pharmaceuticals shares last traded at $13.13, with a volume of 194,820 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ENTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Finally, Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Stock Performance

The stock has a market cap of $392.25 million, a PE ratio of -5.59 and a beta of 0.98. The business’s fifty day moving average price is $13.43 and its 200-day moving average price is $13.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. Analysts forecast that Enanta Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its position in Enanta Pharmaceuticals by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after purchasing an additional 54,396 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $53,252,000. BlackRock Inc. acquired a new position in shares of Enanta Pharmaceuticals during the second quarter worth $47,304,000. Farallon Capital Management LLC raised its stake in Enanta Pharmaceuticals by 30.6% in the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after buying an additional 650,000 shares during the last quarter. Finally, Krensavage Asset Management LLC boosted its stake in Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares in the last quarter. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.